Published in Therap Adv Gastroenterol on May 01, 2010
Use of exclusive enteral nutrition in adults with Crohn's disease: a review. World J Gastroenterol (2013) 0.99
Advances in nutritional therapy in inflammatory bowel diseases: Review. World J Gastroenterol (2016) 0.86
Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience. BMC Gastroenterol (2014) 0.82
Durability of infliximab dose intensification in Crohn's disease. Dig Dis Sci (2011) 0.82
Clinical profiles of moderate and severe Crohn's disease patients and use of anti-tumor necrosis factor agents: Greek expert consensus guidelines. Ann Gastroenterol (2015) 0.80
Pharmacological- and non-pharmacological therapeutic approaches in inflammatory bowel disease in adults. World J Gastrointest Pharmacol Ther (2016) 0.79
Generation and characterization of small single domain antibodies inhibiting human tumor necrosis factor receptor 1. J Biol Chem (2014) 0.78
Indicators of suboptimal biologic therapy over time in patients with ulcerative colitis and Crohn's disease in the United States. PLoS One (2017) 0.75
Systematic review: treatment pattern and clinical effectiveness and safety of pharmaceutical therapies for Crohn's disease in Europe. Clin Exp Gastroenterol (2016) 0.75
A Potential 'Curative' Modality for Crohn's Disease---Modeled after Prophylaxis of Bovine Johne's Disease. Mycobact Dis (2012) 0.75
A systematic review of cost-effectiveness studies comparing conventional, biological and surgical interventions for inflammatory bowel disease. PLoS One (2017) 0.75
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet (2002) 14.14
A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med (1997) 10.67
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial. Lancet (2008) 10.47
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med (2003) 8.49
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology (2006) 6.88
Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med (2004) 6.77
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology (2006) 6.36
Infliximab for the treatment of fistulas in patients with Crohn's disease. N Engl J Med (1999) 6.24
Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med (2005) 5.36
Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med (2006) 5.20
Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med (2007) 4.56
Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med (2007) 4.39
Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology (2004) 4.26
Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut (2007) 4.21
Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med (2007) 4.07
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial. Gastroenterology (2008) 3.98
Predictors of Crohn's disease. Gastroenterology (2006) 3.96
The natural history of corticosteroid therapy for inflammatory bowel disease: a population-based study. Gastroenterology (2001) 3.60
European evidence based consensus on the diagnosis and management of Crohn's disease: current management. Gut (2006) 3.59
Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology (2006) 3.32
Natalizumab for the treatment of active Crohn's disease: results of the ENCORE Trial. Gastroenterology (2007) 3.32
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol (2004) 2.99
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial. Gastroenterology (2006) 2.91
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol (2006) 2.65
Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease. Gut (2007) 2.53
Serum immune responses predict rapid disease progression among children with Crohn's disease: immune responses predict disease progression. Am J Gastroenterol (2006) 2.14
Management of Crohn's disease in adults. Am J Gastroenterol (2001) 2.09
Frequency of glucocorticoid resistance and dependency in Crohn's disease. Gut (1994) 2.06
Long term outcome of patients with active Crohn's disease exhibiting extensive and deep ulcerations at colonoscopy. Am J Gastroenterol (2002) 1.49
Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis (2007) 1.25
Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies. Rev Gastroenterol Disord (2008) 0.78
Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology (2011) 12.09
Tofacitinib, an oral Janus kinase inhibitor, in active ulcerative colitis. N Engl J Med (2012) 5.80
Ustekinumab induction and maintenance therapy in refractory Crohn's disease. N Engl J Med (2012) 4.41
Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis. Gastroenterology (2014) 3.77
Differentiating intestinal tuberculosis from Crohn's disease: a diagnostic challenge. Am J Gastroenterol (2009) 2.99
Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn's disease. Lancet (2005) 2.93
The increasing weight of Crohn's disease subjects in clinical trials: a hypothesis-generatings time-trend analysis. Inflamm Bowel Dis (2013) 2.05
Opposing effects of smoking in ulcerative colitis and Crohn's disease may be explained by differential effects on dendritic cells. Inflamm Bowel Dis (2014) 2.03
NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis (2010) 1.84
Risk of surgery for inflammatory bowel diseases has decreased over time: a systematic review and meta-analysis of population-based studies. Gastroenterology (2013) 1.79
Inflammatory bowel disease: a Canadian burden of illness review. Can J Gastroenterol (2012) 1.73
Surgeon and patient radiation exposure in minimally invasive transforaminal lumbar interbody fusion. J Neurosurg Spine (2008) 1.67
A common CTLA4 haplotype associated with coeliac disease. Eur J Hum Genet (2005) 1.65
Gender differences in healthcare-seeking during common illnesses in a rural community of West Bengal, India. J Health Popul Nutr (2002) 1.64
Normal responses to specific NOD1-activating peptidoglycan agonists in the presence of the NOD2 frameshift and other mutations in Crohn's disease. Eur J Immunol (2006) 1.43
Synergistic enhancement of Toll-like receptor responses by NOD1 activation. Eur J Immunol (2005) 1.37
Incidence of juvenile-onset Crohn's disease in Scotland: association with northern latitude and affluence. Gastroenterology (2004) 1.36
Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut (2008) 1.32
Challenges associated with identifying the environmental determinants of the inflammatory bowel diseases. Inflamm Bowel Dis (2010) 1.31
Characterization of inflammatory bowel disease with urinary metabolic profiling. Am J Gastroenterol (2009) 1.27
Successful infliximab treatment for steroid-refractory celiac disease: a case report. Gastroenterology (2002) 1.26
Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis (2013) 1.25
Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol (2011) 1.24
Chronic exposure to Helicobacter pylori impairs dendritic cell function and inhibits Th1 development. Infect Immun (2006) 1.21
Recommendations for the treatment of ulcerative colitis with infliximab: a gastroenterology expert group consensus. J Crohns Colitis (2012) 1.21
The inflammatory bowel diseases and ambient air pollution: a novel association. Am J Gastroenterol (2010) 1.19
Decreasing colectomy rates for ulcerative colitis: a population-based time trend study. Am J Gastroenterol (2012) 1.12
Effects of mouse and human lipocalin homologues 24p3/lcn2 and neutrophil gelatinase-associated lipocalin on gastrointestinal mucosal integrity and repair. Gastroenterology (2006) 1.10
Environment and the inflammatory bowel diseases. Can J Gastroenterol (2013) 1.07
Isotretinoin and intestinal inflammation: what gastroenterologists need to know. Gut (2009) 1.07
Polyunsaturated fatty acids in inflammatory bowel diseases: a reappraisal of effects and therapeutic approaches. Inflamm Bowel Dis (2013) 1.05
Living with inflammatory bowel disease: A Crohn's and Colitis Canada survey. Can J Gastroenterol Hepatol (2015) 1.03
Modulation of dendritic cell phenotype and function in an in vitro model of the intestinal epithelium. Eur J Immunol (2006) 1.02
O-001 A Multicenter, Double-Blind, Placebo-Controlled Phase3 Study of Ustekinumab, a Human IL-12/23P40 mAB, in Moderate-Service Crohn's Disease Refractory to Anti-TFNα: UNITI-1. Inflamm Bowel Dis (2016) 1.01
Recommendations for the treatment of Crohn's disease with tumor necrosis factor antagonists: an expert consensus report. Inflamm Bowel Dis (2011) 1.01
Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg (2011) 0.99
Looking beyond symptom relief: evolution of mucosal healing in inflammatory bowel disease. Therap Adv Gastroenterol (2011) 0.99
Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut (2010) 0.98
The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut (2011) 0.97
Postoperative complications following colectomy for ulcerative colitis: a validation study. BMC Gastroenterol (2012) 0.96
TRPM8 activation attenuates inflammatory responses in mouse models of colitis. Proc Natl Acad Sci U S A (2013) 0.94
Non-specific abdominal pain and air pollution: a novel association. PLoS One (2012) 0.92
Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol (2011) 0.92
Liver diseases associated with anti-tumor necrosis factor-alpha (TNF-α) use for inflammatory bowel disease. Inflamm Bowel Dis (2011) 0.90
Domino ring-opening metathesis-ring-closing metathesis of bicyclo[2.2.2]octene derivatives: scope and limitations. J Org Chem (2012) 0.90
Vitamin D and gastrointestinal diseases: inflammatory bowel disease and colorectal cancer. Therap Adv Gastroenterol (2011) 0.90
Endoscopic and histologic features of sodium phosphate bowel preparation-induced colonic ulceration: case report and review. Gastrointest Endosc (2002) 0.89
Gastric fundic gland polyps in south-east Scotland: absence of adenomatous polyposis coli gene mutations and a strikingly low prevalence of Helicobacter pylori infection. J Gastroenterol Hepatol (2002) 0.89
Learning the lessons of antitumour necrosis factor therapy-associated psoriasis. Can J Gastroenterol (2009) 0.88
Detection of muramyl dipeptide-sensing pathway defects in patients with Crohn's disease. Inflamm Bowel Dis (2006) 0.88
Intraoperative electromyography monitoring in minimally invasive transforaminal lumbar interbody fusion. J Neurosurg Spine (2007) 0.88
New insights into gastrointestinal and hepatic granulomatous disorders. Nat Rev Gastroenterol Hepatol (2011) 0.87
Effect of fish oil enriched enteral diet on inflammatory bowel disease tissues in organ culture: differential effects on ulcerative colitis and Crohn's disease. World J Gastroenterol (2005) 0.86
Ambient ozone concentrations and the risk of perforated and nonperforated appendicitis: a multicity case-crossover study. Environ Health Perspect (2013) 0.85
Infliximab use in Crohn's disease: impact on health care resources in the UK. Eur J Gastroenterol Hepatol (2005) 0.85
Infliximab in refractory coeliac disease. Eur J Gastroenterol Hepatol (2005) 0.85
Atomic water channel controlling remarkable properties of a single brain microtubule: correlating single protein to its supramolecular assembly. Biosens Bioelectron (2013) 0.85
Clostridium difficile infection worsens the prognosis of ulcerative colitis. Can J Gastroenterol Hepatol (2014) 0.84
Inflammatory bowel disease cause-specific mortality: a primer for clinicians. Inflamm Bowel Dis (2014) 0.84
Influences of intestinal bacteria in human inflammatory bowel disease. Infect Dis Clin North Am (2010) 0.83
Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin. Drugs (2006) 0.83
Domino metathesis involving ROM-RCM of substituted norbornenes. Rapid access to densely functionalized tricyclic bridged and condensed ring systems. Org Lett (2007) 0.82
Increasing prevalence of Salmonella enterica serotype Paratyphi-A in patients with enteric fever in a periurban slum setting of Kolkata, India. Int J Environ Health Res (2006) 0.82
Advances in novel diagnostic endoscopic imaging techniques in inflammatory bowel disease. Inflamm Bowel Dis (2013) 0.82
Talking about life and IBD: A paradigm for improving patient-physician communication. J Crohns Colitis (2008) 0.82
New polyoxometalates containing hybrid polymers and their potential for nano-patterning. Chemistry (2014) 0.81
The positioning of colectomy in the treatment of ulcerative colitis in the era of biologic therapy. Inflamm Bowel Dis (2013) 0.81
Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis (2013) 0.81
Synthesis of fused cyclic systems containing medium-sized rings through tandem ROM-RCM of norbornene derivatives embedded in a carbohydrate template. J Org Chem (2009) 0.81
Effect of adalimumab on clinical laboratory parameters in patients with Crohn's disease: results from the CHARM trial. Inflamm Bowel Dis (2011) 0.81
Management of the pregnant inflammatory bowel disease patient on anti-tumour necrosis factor: state of the art and future directions. Can J Gastroenterol Hepatol (2014) 0.80
Use of growth-hormone-releasing peptide-6 (GHRP-6) for the prevention of multiple organ failure. Clin Sci (Lond) (2006) 0.80
Dynamic position change at colonoscopy improves adenoma detection. Can J Gastroenterol (2013) 0.80
Resonant oscillation language of a futuristic nano-machine-module: eliminating cancer cells & Alzheimer aβ plaques. Curr Top Med Chem (2015) 0.80
Operational feasibility of implementing community-based zinc supplementation: impact on childhood diarrheal morbidity. Pediatr Infect Dis J (2007) 0.80
Radiation-sensitive novel polymeric resist materials: iterative synthesis and their EUV fragmentation studies. ACS Appl Mater Interfaces (2014) 0.80
Advances in the diagnosis and management of inflammatory bowel disease: challenges and uncertainties. Saudi J Gastroenterol (2014) 0.79
Combination treatment with theranostic nanoparticles for glioblastoma sensitization to TMZ. Mol Imaging Biol (2014) 0.79
NOD2 activity modulates the phenotype of LPS-stimulated dendritic cells to promote the development of T-helper type 2-like lymphocytes - Possible implications for NOD2-associated Crohn's disease. J Crohns Colitis (2007) 0.79
Coeliac disease and the risk of infections. Gut (2008) 0.79
Managing the risks of IBD therapy. Curr Gastroenterol Rep (2009) 0.79
Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis (2016) 0.79
Estimating benefits of therapy in Crohn's disease in terms of indirect costs. Can J Gastroenterol (2011) 0.78
Is portal hypertension associated with protein-losing enteropathy? J Gastroenterol Hepatol (2005) 0.78
Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of NI-0401 (a fully human anti-CD3 monoclonal antibody) in patients with moderate to severe active Crohn's disease. Inflamm Bowel Dis (2010) 0.78
Survey on the use of adalimumab as maintenance therapy in Crohn's disease in England and Ireland. Eur J Gastroenterol Hepatol (2010) 0.78
Beyond TNF, Th1 and Th2 in inflammatory bowel disease. Gut (2008) 0.78
Novel CD8+ T-Cell Subsets Demonstrating Plasticity in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis (2016) 0.78
An evaluation of the use of serum 7-alpha-hydroxycholestenone as a diagnostic test of bile acid malabsorption causing watery diarrhea. Can J Gastroenterol (2011) 0.77
Synthetic studies on schisandra nortriterpenoids. Stereocontrolled synthesis of enantiopure C-5-epi ABC ring systems of micrandilactone A and lancifodilactone G using RCM. J Org Chem (2010) 0.77
Routine duodenal biopsies to diagnose celiac disease. Can J Gastroenterol (2013) 0.77
Immunogenicity of Influenza Vaccine for Patients with Inflammatory Bowel Disease on Maintenance Infliximab Therapy: A Randomized Trial. Inflamm Bowel Dis (2016) 0.77
Anti-tumor necrosis factor therapy and influenza: keeping it in perspective. Therap Adv Gastroenterol (2010) 0.77
Multidisciplinary teams as standard of care in inflammatory bowel disease. Can J Gastroenterol (2013) 0.77
Bowel Ultrasonography in the Management of Crohn's Disease. A Review with Recommendations of an International Panel of Experts. Inflamm Bowel Dis (2016) 0.77
Human pancreatic secretory trypsin inhibitor stabilizes intestinal mucosa against noxious agents. Am J Pathol (2007) 0.76
Is rosiglitazone a promising treatment for ulcerative colitis? Nat Clin Pract Gastroenterol Hepatol (2008) 0.76
Nutrient modulation of autophagy: implications for inflammatory bowel diseases. Inflamm Bowel Dis (2013) 0.76
The classics in perspective. Gut (2007) 0.76